A detailed history of Advisor Group Holdings, Inc. transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 1,200 shares of CLSD stock, worth $1,224. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,200
Previous 1,200 -0.0%
Holding current value
$1,224
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.08 - $1.58 $648 - $948
-600 Reduced 33.33%
1,200 $1,000
Q1 2024

May 10, 2024

BUY
$1.2 - $2.02 $960 - $1,616
800 Added 80.0%
1,800 $2,000
Q4 2023

Feb 12, 2024

SELL
$0.68 - $1.18 $680 - $1,180
-1,000 Reduced 50.0%
1,000 $1,000
Q3 2023

Nov 13, 2023

BUY
$0.82 - $1.27 $491 - $762
600 Added 42.86%
2,000 $1,000
Q2 2023

Aug 10, 2023

SELL
$0.97 - $1.48 $6,353 - $9,694
-6,550 Reduced 82.39%
1,400 $1,000
Q1 2023

May 12, 2023

SELL
$0.93 - $1.66 $1,860 - $3,320
-2,000 Reduced 20.1%
7,950 $8,000
Q3 2022

Nov 14, 2022

SELL
$1.08 - $1.83 $2,592 - $4,392
-2,400 Reduced 19.43%
9,950 $11,000
Q1 2022

May 04, 2022

BUY
$1.35 - $2.88 $4,050 - $8,640
3,000 Added 32.09%
12,350 $28,000
Q3 2021

Nov 05, 2021

BUY
$4.83 - $7.2 $9,418 - $14,040
1,950 Added 26.35%
9,350 $56,000
Q2 2021

Aug 02, 2021

BUY
$2.32 - $5.38 $11,600 - $26,900
5,000 Added 208.33%
7,400 $36,000
Q2 2020

Aug 14, 2020

SELL
$1.55 - $2.41 $387 - $602
-250 Reduced 9.43%
2,400 $5,000
Q1 2020

May 18, 2020

BUY
$1.32 - $3.77 $3,498 - $9,990
2,650 New
2,650 $4,000

Others Institutions Holding CLSD

About Clearside Biomedical, Inc.


  • Ticker CLSD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,190,700
  • Market Cap $61.4M
  • Description
  • Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...
More about CLSD
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.